We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Metabonomics for MolPAGE Discovering Diabetes Biomarkers


MolPAGE (Molecular Phenotyping to Accelerate Genomic Epidemiology) is an EU consortium with almost twenty collaborating universities and companies throughout Europe. One of the aims of MolPAGE is to find early onset biomarkersfor type 2 diabetes (T2DM) and cardio-vascular diseases(CVD). Novo Nordisk in Denmark and Imperial College in London are the two partners cooperating closely within the area of metabonomics. Novo Nordisk commitment in MolPAGE also covers transcriptomics.